News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Essentially I think they will take the money out of the market once the new entity has a valuation!
CBIO will have the rights excluding the profitable China!
So the listing should reflect the potential value of the new entity!
Up to there we dance...
Then the market will tell if this stuff is standing!
... we can spread a pitiful veil on how the market works...
So assuming that there is a market maneuverer who has given the green light to the operation, otherwise what would be the point of doing it, I expect that the new entity will receive an evaluation!
Could it currently be a bear trap for retail investors?
watch out
I added at 0,294
fuck the shorts!
GNI Group reported its Consolidated Financial Results for its Fiscal Year 2022 on February 15, 2023 showing continued revenue and profit growth from pirfenidone sales in China for the treatment of idiopathic pulmonary fibrosis, which includes revenue of approximately $102 million and net profit of approximately $23 million.
https://www.daiwair.co.jp/td_download.cgi?c=2160&i=2522199
Sales 2022 120 M
Net income 2022 8,06 M
Net Debt 2022 -
Capitalization 371 M
Jefferies Adjusts GNI's Price Target to 1,300 Yen From 2,100 Yen, Keeps at Buy
02/27/2023 | 05:18am EST
Now 1078
Continent is profitable with a robust fibrosis pipeline in various stages of development, including a Phase 3 study of F351 in HBV associated fibrosis and a Phase 2 study poised to initiate in NASH fibrosis.”
The quastion is: 2.5% of that, How much is it worth?
the merger must be voted on!
I wouldn't go short!
So..
The Company's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT.
This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog
alfa (MarzAA)"
if the merger is approved, the loot goes to whoever has the cvr otherwise to everyone...
keep going short LOLOLOL
MC just $ 15 mil....
perhaps I add
Thank you for further potential cash distributions
How much is this deal worth?
I think $1 is within reach!
Merger getting closer
dancing in the next days!
IMO it's just the beginning...
I guess they will ask to vote soon
https://www.daiwair.co.jp/td_download.cgi?c=2160&i=2522199
Both the conversion of the Series X preferred stock and the acquisition of a 65.18% interest in Continent will be subject to Catalyst stockholder approval, which will be sought in 2023. If the acquisition is approved by stockholders, Catalyst would issue at closing a total of up to 1,110,776,224 shares of common stock for a controlling interest in Continent, at which point Catalyst would expect to consolidate results of operations with Continent.
“The asset purchase of F351 and the subsequent business combination with Continent allows CBIO to both accelerate the return of cash to stockholders and provide additional value to our stockholders through equity ownership of Continent and a CVR for the monetization of our legacy assets,” said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. “The company is continuing its efforts to monetize the legacy assets, and we expect to distribute additional cash in 2023. We believe that this set of transactions creates an attractive fibrosis company with further upside for our stockholders. Continent is profitable with a robust fibrosis pipeline in various stages of development, including a Phase 3 study of F351 in HBV associated fibrosis and a Phase 2 study poised to initiate in NASH fibrosis.”
I have to say I really can't complain here!
Well done!
We need a short squeeze as icing on the cake and if it comes I applaud!
Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction
Announces $7.5 Million Special Dividend and Contingent Value Right (CVR)
On December 26, 2022, Catalyst Biosciences, Inc., a Delaware corporation (?Catalyst?), acquired the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (?GNI Japan?), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (?GNI Hong Kong? and, together with GNI Japan, the ?Sellers?), pursuant to that certain Asset Purchase Agreement, dated December 26 2022 (the ?F351 Agreement?), by and among Catalyst and the Sellers. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to the Sellers? proprietary Hydronidone compound (collectively, the ?F351 Assets?), other than such assets and intellectual property rights located in the People?s Republic of China. The F351 Assets include 15 issued or pending patents and patent applications outside of the People?s Republic of China, with the last acquired issued patent expected to expire in August 2037.
Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement (the ?F351 Effective Time?), Catalyst paid the Sellers $35,000,000 in the form of: 6,266,521 shares of Catalyst common stock, par value $0.001 per share (the ?Catalyst Common Stock?); and 12,340 shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the ?Catalyst Convertible Preferred Stock? and collectively with the Catalyst Common Stock issued pursuant to the F351 Agreement, the ?Catalyst F351 Securities?).
Each of Catalyst and the Sellers has agreed to customary representations, warranties and covenants in the F351 Agreement, including, among others, covenants relating to (1) Catalyst filing with the U.S. Securities and Exchange Commission (the ?SEC?) and causing to become effective a registration statement (the ?Registration Statement?) to register (a) the shares of Catalyst Common Stock issued pursuant to the F351 Agreement, and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, (2) Catalyst using reasonable best efforts to maintain the existing listing of the Catalyst Common Stock on The Nasdaq Stock Market LLC (?Nasdaq?) and Catalyst causing the (a) shares of Catalyst Common Stock issued in connection with the F351 Agreement and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, to be approved for listing on Nasdaq, and (3) the Sellers assuming and paying, discharging, performing or otherwise satisfying the liabilities and obligations of any kind and nature relating to the Purchased Contracts (as defined in the F351 Agreement).
Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction
Announces $7.5 Million Special Dividend and Contingent Value Right (CVR)
On December 26, 2022, Catalyst Biosciences, Inc., a Delaware corporation (?Catalyst?), acquired the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (?GNI Japan?), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (?GNI Hong Kong? and, together with GNI Japan, the ?Sellers?), pursuant to that certain Asset Purchase Agreement, dated December 26 2022 (the ?F351 Agreement?), by and among Catalyst and the Sellers. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to the Sellers? proprietary Hydronidone compound (collectively, the ?F351 Assets?), other than such assets and intellectual property rights located in the People?s Republic of China. The F351 Assets include 15 issued or pending patents and patent applications outside of the People?s Republic of China, with the last acquired issued patent expected to expire in August 2037.
Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement (the ?F351 Effective Time?), Catalyst paid the Sellers $35,000,000 in the form of: 6,266,521 shares of Catalyst common stock, par value $0.001 per share (the ?Catalyst Common Stock?); and 12,340 shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the ?Catalyst Convertible Preferred Stock? and collectively with the Catalyst Common Stock issued pursuant to the F351 Agreement, the ?Catalyst F351 Securities?).
Each of Catalyst and the Sellers has agreed to customary representations, warranties and covenants in the F351 Agreement, including, among others, covenants relating to (1) Catalyst filing with the U.S. Securities and Exchange Commission (the ?SEC?) and causing to become effective a registration statement (the ?Registration Statement?) to register (a) the shares of Catalyst Common Stock issued pursuant to the F351 Agreement, and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, (2) Catalyst using reasonable best efforts to maintain the existing listing of the Catalyst Common Stock on The Nasdaq Stock Market LLC (?Nasdaq?) and Catalyst causing the (a) shares of Catalyst Common Stock issued in connection with the F351 Agreement and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, to be approved for listing on Nasdaq, and (3) the Sellers assuming and paying, discharging, performing or otherwise satisfying the liabilities and obligations of any kind and nature relating to the Purchased Contracts (as defined in the F351 Agreement).
|
Followers
|
28
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
560
|
|
Created
|
11/07/05
|
Type
|
Free
|
| Moderators | |||
All currently approved medicines for hemophilia are injected into a patient’s veins – at Catalyst, we believe that a clotting factor that could instead be injected just under the skin would enhance the treatment, and lives, of patients with hemophilia.
Catalyst is focused on the prevention of spontaneous bleeding in hemophilia, even during surgery, using our potent, coagulation factors to promote blood clotting. We plan to initiate two clinical trials in 2017, one in patients with Hemophilia B using our next-generation Factor IX, CB 2679d, and the other in hemophilia inhibitor patients using our next-generation Factor VIIa, marzeptacog alfa (activated) (formerly known as CB 813d).
Hemophilia patients suffer from spontaneous bleeding episodes and substantially prolonged bleeding times that can become limb- or life-threatening following injury or trauma. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in permanent, disabling joint damage. Hemophilia results from a genetic or acquired deficiency of a protein required for normal blood coagulation.
Hemophilia patients are currently treated with replacement therapy of key coagulation proteins, Factor VIII for Hemophilia A or Factor IX for Hemophilia B. A complication for hemophilia patients receiving factor replacement therapy is the production of antibodies against the replacement factor, also called inhibitors. The overall prevalence of inhibitor formation is up to 30% in patients with hemophilia A and up to 5% in patients with hemophilia B.
Inhibitor patients are treated with what are known as “bypass” agents that initiate coagulation by a pathway that is independent of Factor VIII or Factor IX. There are currently two approved “bypass agents”, Factor VIIa (for example NovoSeven™) and FEIBA™. However, current hemophilia drugs for patients with inhibitors have significant limitations regarding potency, duration of action and often require frequent dosing – and they are all injected intravenously which is not ideal for patients who predominantly take these medicines at home.
We believe that the shortcomings of currently approved therapies are barriers to prophylactic treatment strategies that, if surmounted, could provide meaningfully improved long-term clinical outcomes for patients. Catalyst's engineered proteases in the fields of hemostasis are designed to overcome the significant limitations of current treatment options, facilitate preventative treatment, and ultimately deliver substantially better outcomes for patients.
Catalyst created a portfolio of improved Factor IX proteases, including the clinical development candidate CB 2679d for treatment of hemophilia B, a life-long disease caused by a genetic deficiency in coagulation Factor IX.
The leading recombinant human Factor IX on the market for treating acute bleeding episodes in hemophilia B patients has a short half-life and is therefore not ideal for prophylactic treatment.
CB 2679d has shown significantly higher potency in pre-clinical studies versus other FIX products on the market and in development. Based on data from well-validated animal models of hemophilia, CB 2679d may provide hemophilia B patients with a viable subcutaneous prophylactic therapy.
Catalyst has a collaboration with ISU Abxis to advance the development of CB 2679d through Phase 1/2 proof-of-concept study in hemophilia B patients. After Phase 1, ISU Abxis retains exclusive commercial rights in Korea while Catalyst retains full development and commercial rights for CB 2679d outside of Korea.
Marzeptacog alfa (activated) (formerly known as CB 813d) is a next-generation Factor VIIa that was designed to allow for the effective, long-term, prophylaxis in hemophilia patients with inhibitors. Catalyst has successfully completed an intravenous Phase 1 clinical trial in patients with severe hemophilia A and B with and without inhibitors.
Catalyst designed marzeptacog alfa (activated) (formerly known as CB 813d) to combine higher clot-generating activity at the site of bleeding and improved efficacy. Catalyst anticipates that this product candidate could be used for subcutaneous prophylactic treatment.
Positive results from an open label, multicenter Phase 1 intravenous dosing clinical trial of marzeptacog alfa (activated) (formerly known as CB 813d) were reported in June 2015. Marzeptacog alfa (activated) (formerly known as CB 813d) was given intravenously to 25 non-bleeding hemophilia patients in single ascending dose cohorts who were then observed for up to 60 days post treatment. Results showed that single doses of marzeptacog alfa (activated) (formerly known as CB 813d) were well tolerated when administered to hemophilia A and B patients, and there were no instances of antibody response or thrombosis. Marzeptacog alfa (activated) (formerly known as CB 813d) demonstrated pharmacological efficacy as measured by significant shortening of aPTT (activated partial thromboplastin time) and PT (prothrombin time) for up to 48 hours post dosing. The results were presented in a poster session at the International Society on Thrombosis and Haemostasis (ISTH) Meeting in June 2015.
Catalyst has identified Factor Xa variants that have enhanced potency, improved safety, and superior duration of action in preclinical models of bleeding compared with a competing Factor Xa in clinical development. Catalyst believes that a safe and effective Factor Xa product has the potential to be used both to treat hemophilia patients and to reduce blood loss in trauma and surgery in patients with normal coagulation systems and clotting activity or those who are taking anti-platelet agents or anticoagulants.
Catalyst’s FXa program has reached the lead candidate stage of research and is available for partnering.
Catalyst has developed and optimized a propriety method to create novel proteases that include anti-C3 protease assets such as CB 2782 for ischemia-reperfusion injury such as delayed graft function (DGF) after kidney transplantation and the preclinical leads in the dry age-related macular degeneration (AMD) program. In 2016, Catalyst reduced resources deployed towards its anti-complement research programs and all related research activities were discontinued. These assets are available for partnering.
The complement cascade is a series of molecular processes that plays a central role in the body’s inflammatory and immune responses and helps to localize specific immune system cells at the site of infection or inflammation. Drugs that target the complement cascade could potentially be used in a number of indications, including prevention of transplant rejection, age-related macular degeneration, cardiovascular disease, pulmonary diseases, and autoimmune disease.
CB 2782 is a novel protease derived from human membrane type serine protease 1 (MTSP-1) that cleaves complement factor 3 (C3) and may be developed to prevent delayed graft function (DGF) following kidney transplant as a result of ischemia-reperfusion injury. Other opportunities might include coronary artery bypass graft (CABG), acute myocardial infarction (AMI), and stroke. Catalyst also has earlier stage, distinct anti-complement lead molecules for dry age-related macular degeneration (dry AMD) and other chronic, and selected orphan, diseases.
Catalyst created improved protease variants using a rational design strategy. In this process, a small number of amino acids in a given protease are substituted in an iterative fashion with different amino acids to improve a molecule’s biological properties. This approach led to product candidates that have the potential to be improved versions of Factor VIIa, Factor IX, and Factor Xa that may have many important and differentiated advantages including higher activity, longer duration of action, and improved safety.
Catalyst has developed and optimized a propriety method to create novel proteases that currently make up part of our partnering portfolio, including our anti-C3 proteases including CB 2782 for delayed graft function (DGF) and the leads in our dry age-related macular degeneration (AMD) program. In September 2016, Catalyst reduced resources deployed towards its anti-complement research programs and all related research activities were discontinued. Catalyst intends to explore licensing opportunities for its anti-complement programs in DGF and Dry AMD.
